Posted by Michael Wonder on 05 Jan 2016

CADTH calls for patient input on a submission from Gilead on new combination treatment for patients with HIV infection

CADTH

4 January 2016 - CADTH has received the following notice of a pending submission from Gilead for emtricitabine with tenofovir alafenamide for patients with HIV infection.

For more details, go to: https://www.cadth.ca/emtricitabine-tenofovir-alafenamide

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Combination product , Canada , Submission